• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Novel human antibody protects mice from H7N9 flu virus [PreClinical]

byJudith KandelandJessica Lau
August 28, 2015
in Chronic Disease, Infectious Disease, Preclinical
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. VIS410, a human antibody which targets the hemagglutinin (HA) glycoprotein on the surface of flu viruses, showed strong binding to a variety of influenza A virus strains based on computational and in vitro experiments.

2. Administration of VIS410 either alone or in combination with oseltamivir, a neuraminidase inhibitor, led to increased survival and mitigated cytokine response in various mouse models of H7N9 challenge.

Evidence Rating Level: 2 (Good)    

Study Rundown: Influenza virus remains a significant cause of human mortality and morbidity, and particularly virulent strains such as H7N9 are associated with greater adverse patient outcomes despite available treatments. Current flu vaccines use inactivated virus antigens to provoke antibody production, and infections are also therapeutically treated with neuraminidase inhibitors such as oseltamivir. This work instead tested an antibody to broadly target HA in H7N9 and other virus strains, for use as a pre- or post-infection treatment.

The authors first used computational methods to design the VIS410 antibody candidate based on its ability to bind HAs from multiple virus strains. In vitro experiments confirmed predicted binding affinities. In an initial set of animal experiments, one-time therapeutic administration of VIS410 increased survival in mice given a lethal dose of the H3N2 strain. In a mouse model of lethal H7N9 challenge, treatment with VIS410 alone or with daily administration of oseltamivir increased survival when compared to oseltamivir treatment alone. In a separate murine model of sublethal H7N9 challenge, mice prophylactically given VIS410 in combination with twice daily oseltamivir showed lower lung cytokine levels than those given mock treatment.

Overall, this work represents a promising new and potent antibody-based approach to treating influenza infection. Future work should address optimization of VIS410 administration, including whether it should be given prophylactically or therapeutically. Additionally, safety of VIS410 must be rigorously evaluated before the drug can be considered for clinical use.

RELATED REPORTS

Influenza is associated with an increased odds of Parkinson Disease diagnosis after 10 years

Antiviral agents such as zanamivir and baloxavir are associated with improved time to symptom alleviation for seasonal influenza

#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

Click to read the study in PNAS

Relevant Reading: Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection

In-Depth [animal study]: Initial computational experiments focused on developing an antibody to bind to the HA stem region, whose highly interconnected trimeric interface may be more resistant to mutation than other HA regions. In vitro enzyme-linked immunosorbent assays confirmed the high binding affinity of VIS410 for a variety of flu viruses, with dissociation constants measuring 50-730 pM.

An initial baseline animal experiment involved challenging BALB/c mice with a lethal intranasal dose of H3N2. Intraperitoneal administration of 2.5-20 mg/kg VIS410 48 hours after exposure increased survival compared to placebo-treated mice (p<0.001, n=10-15 per group). Next, DBA mice were used to model lethal H7N9 infection, since they are more sensitive to influenza infection than other mice. Mice given 50 mg/kg VIS410 24 hours before H7N9 exposure and again 48 hours after exposure showed increased survival over mice given 50 mg/kg oseltamivir twice daily for 8 days (p=0.015, n=10 per group). Combining one dose of VIS410 with daily oseltamivir treatment improved survival as compared to administering oseltamivir alone (p<0.001, n=10 per group).

A third animal model involved subjecting C57BL/6 mice to a sublethal dose of H7N9. Animals given 50 mg/kg VIS410 at 12 hours before infection combined with 40 mg/kg oseltamivir twice daily showed lower lung viral loads than mock-treated animals at 5 days following inoculation (p=0.002, n=6 per group). In comparison to mock-treated mice, the combination-treated animals also showed lower levels of several cytokines, including monocyte chemotactic protein-3 (MCP-3), interferon gamma-induced protein 10 (IP-10), and macrophage inflammatory protein 1α (MIP-1α) (p<0.05 for each, n=3 per group).

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: influenza
Previous Post

Sleep deprivation in attending physicians not linked to adverse outcomes in elective daytime surgical procedures

Next Post

Teens identifying with goth subculture at higher risk of depression and self-harm

RelatedReports

Influenza vaccine not associated with increased risk of epilepsy in children
Infectious Disease

Influenza is associated with an increased odds of Parkinson Disease diagnosis after 10 years

October 26, 2021
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Emergency

Antiviral agents such as zanamivir and baloxavir are associated with improved time to symptom alleviation for seasonal influenza

August 16, 2021
#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines
StudyGraphics

#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

November 26, 2020
Influenza vaccine not associated with increased risk of epilepsy in children
Infectious Disease

Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

November 22, 2020
Next Post
High dose antidepressants may increase self-harm risk among children, young adults

Teens identifying with goth subculture at higher risk of depression and self-harm

Pediatric pulmonary hypertension, a growing healthcare burden

Combination therapy associated with improved outcomes in pulmonary arterial hypertension

No significant improvement in older adult cognitive function with moderate physical activity

No significant improvement in older adult cognitive function with moderate physical activity

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.